628 related articles for article (PubMed ID: 26693397)
41. Population-wide principal component-based quantification of blood-brain-barrier dynamics in multiple sclerosis.
Shinohara RT; Crainiceanu CM; Caffo BS; Gaitán MI; Reich DS
Neuroimage; 2011 Aug; 57(4):1430-46. PubMed ID: 21635955
[TBL] [Abstract][Full Text] [Related]
42. Use of perfusion- and diffusion-weighted imaging in differential diagnosis of acute and chronic ischemic stroke and multiple sclerosis.
Zivadinov R; Bergsland N; Stosic M; Sharma J; Nussenbaum F; Durfee J; Hani N; Abdelrahman N; Jaisani Z; Minagar A; Hoque R; Munschauer FE; Dwyer MG
Neurol Res; 2008 Oct; 30(8):816-26. PubMed ID: 18826808
[TBL] [Abstract][Full Text] [Related]
43. Multiple sclerosis lesion formation and early evolution revisited: A weekly high-resolution magnetic resonance imaging study.
Guttmann CR; Rousset M; Roch JA; Hannoun S; Durand-Dubief F; Belaroussi B; Cavallari M; Rabilloud M; Sappey-Marinier D; Vukusic S; Cotton F
Mult Scler; 2016 May; 22(6):761-9. PubMed ID: 26362901
[TBL] [Abstract][Full Text] [Related]
44. White-matter lesions drive deep gray-matter atrophy in early multiple sclerosis: support from structural MRI.
Mühlau M; Buck D; Förschler A; Boucard CC; Arsic M; Schmidt P; Gaser C; Berthele A; Hoshi M; Jochim A; Kronsbein H; Zimmer C; Hemmer B; Ilg R
Mult Scler; 2013 Oct; 19(11):1485-92. PubMed ID: 23462349
[TBL] [Abstract][Full Text] [Related]
45. Low degree of cortical pathology is associated with benign course of multiple sclerosis.
Calabrese M; Favaretto A; Poretto V; Romualdi C; Rinaldi F; Mattisi I; Morra A; Perini P; Gallo P
Mult Scler; 2013 Jun; 19(7):904-11. PubMed ID: 23069877
[TBL] [Abstract][Full Text] [Related]
46. Disability in multiple sclerosis is related to normal appearing brain tissue MTR histogram abnormalities.
Traboulsee A; Dehmeshki J; Peters KR; Griffin CM; Brex PA; Silver N; Ciccarrelli O; Chard DT; Barker GJ; Thompson AJ; Miller DH
Mult Scler; 2003 Dec; 9(6):566-73. PubMed ID: 14664468
[TBL] [Abstract][Full Text] [Related]
47. Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis.
Calabrese M; De Stefano N; Atzori M; Bernardi V; Mattisi I; Barachino L; Morra A; Rinaldi L; Romualdi C; Perini P; Battistin L; Gallo P
Arch Neurol; 2007 Oct; 64(10):1416-22. PubMed ID: 17923625
[TBL] [Abstract][Full Text] [Related]
48. Choline is increased in pre-lesional normal appearing white matter in multiple sclerosis.
Tartaglia MC; Narayanan S; De Stefano N; Arnaoutelis R; Antel SB; Francis SJ; Santos AC; Lapierre Y; Arnold DL
J Neurol; 2002 Oct; 249(10):1382-90. PubMed ID: 12382153
[TBL] [Abstract][Full Text] [Related]
49. Bi-exponential diffusion signal decay in normal appearing white matter of multiple sclerosis.
Nagy SA; Aradi M; Orsi G; Perlaki G; Kamson DO; Mike A; Komaromy H; Schwarcz A; Kovacs A; Janszky J; Pfund Z; Illes Z; Bogner P
Magn Reson Imaging; 2013 Feb; 31(2):286-95. PubMed ID: 22902473
[TBL] [Abstract][Full Text] [Related]
50. T2 MRI texture analysis is a sensitive measure of tissue injury and recovery resulting from acute inflammatory lesions in multiple sclerosis.
Zhang Y; Zhu H; Mitchell JR; Costello F; Metz LM
Neuroimage; 2009 Aug; 47(1):107-11. PubMed ID: 19361563
[TBL] [Abstract][Full Text] [Related]
51. A novel method for automatic determination of different stages of multiple sclerosis lesions in brain MR FLAIR images.
Khayati R; Vafadust M; Towhidkhah F; Nabavi SM
Comput Med Imaging Graph; 2008 Mar; 32(2):124-33. PubMed ID: 18055174
[TBL] [Abstract][Full Text] [Related]
52. Fluid-attenuated inversion recovery magnetic resonance imaging detects cortical and juxtacortical multiple sclerosis lesions.
Bakshi R; Ariyaratana S; Benedict RH; Jacobs L
Arch Neurol; 2001 May; 58(5):742-8. PubMed ID: 11346369
[TBL] [Abstract][Full Text] [Related]
53. Automated segmentation of changes in FLAIR-hyperintense white matter lesions in multiple sclerosis on serial magnetic resonance imaging.
Schmidt P; Pongratz V; Küster P; Meier D; Wuerfel J; Lukas C; Bellenberg B; Zipp F; Groppa S; Sämann PG; Weber F; Gaser C; Franke T; Bussas M; Kirschke J; Zimmer C; Hemmer B; Mühlau M
Neuroimage Clin; 2019; 23():101849. PubMed ID: 31085465
[TBL] [Abstract][Full Text] [Related]
54. An automated tool for detection of FLAIR-hyperintense white-matter lesions in Multiple Sclerosis.
Schmidt P; Gaser C; Arsic M; Buck D; Förschler A; Berthele A; Hoshi M; Ilg R; Schmid VJ; Zimmer C; Hemmer B; Mühlau M
Neuroimage; 2012 Feb; 59(4):3774-83. PubMed ID: 22119648
[TBL] [Abstract][Full Text] [Related]
55. T1- Thresholds in Black Holes Increase Clinical-Radiological Correlation in Multiple Sclerosis Patients.
Thaler C; Faizy T; Sedlacik J; Holst B; Stellmann JP; Young KL; Heesen C; Fiehler J; Siemonsen S
PLoS One; 2015; 10(12):e0144693. PubMed ID: 26659852
[TBL] [Abstract][Full Text] [Related]
56. Multiple sclerosis: hyperintense lesions in the brain on nonenhanced T1-weighted MR images evidenced as areas of T1 shortening.
Janardhan V; Suri S; Bakshi R
Radiology; 2007 Sep; 244(3):823-31. PubMed ID: 17690319
[TBL] [Abstract][Full Text] [Related]
57. A serial study of new MS lesions and the white matter from which they arise.
Goodkin DE; Rooney WD; Sloan R; Bacchetti P; Gee L; Vermathen M; Waubant E; Abundo M; Majumdar S; Nelson S; Weiner MW
Neurology; 1998 Dec; 51(6):1689-97. PubMed ID: 9855524
[TBL] [Abstract][Full Text] [Related]
58. Longitudinal associations between brain structural changes and fatigue in early MS.
Nourbakhsh B; Azevedo C; Nunan-Saah J; Maghzi AH; Spain R; Pelletier D; Waubant E
Mult Scler Relat Disord; 2016 Jan; 5():29-33. PubMed ID: 26856940
[TBL] [Abstract][Full Text] [Related]
59. Choroid Plexus Enlargement in Inflammatory Multiple Sclerosis: 3.0-T MRI and Translocator Protein PET Evaluation.
Ricigliano VAG; Morena E; Colombi A; Tonietto M; Hamzaoui M; Poirion E; Bottlaender M; Gervais P; Louapre C; Bodini B; Stankoff B
Radiology; 2021 Oct; 301(1):166-177. PubMed ID: 34254858
[TBL] [Abstract][Full Text] [Related]
60. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
